שיטה חדשנית לטיפול בגידולי ראש פותחה בישראל

Alternating electric fields shrink recurrent glioblastoma tumors Martha Kerr Reuters Health Last Updated: 2008-04-14 17:55:11 -0400 (Reuters Health) NEW YORK (Reuters Health) - An investigational device in phase I/II trials that exposes tumors to alternating electric fields has been shown to shrink recurrent glioblastomas AND can more than double survival time. Some patients are still alive 4 years later, researchers announced at the annual meeting of the American Association for Cancer Research that is being held this week in San Diego, California. Results with the Tumor Treating Field (TTF) device were presented Sunday by principal investigator Dr. Yoram Palti of NovoCure Ltd, of Haifa, Israel. "The device is approximately the size of a laptop, with electrodes placed over the site of tumor -- the glioblastoma, in this case," Dr. Palti said in an interview with Reuters Health after his presentation. The TTF device is also being tested in breast cancer, AND a trial in lung cancer has just begun. TTFs are "specially tuned, low-intensity, intermediate-frequency, alternating electric fields," Dr. Palti explained in his presentation to meeting attendees. Preclinical studies show that the TTFs effectively inhibit cancer cell proliferation in culture AND in animal tumor models. The electrical field has an inhibitory effect only on actively dividing cells. "It appears to act in a few different ways," Dr. Palti explained. "Electrical vibrations cause the cell to disintegrate... In part, it acts through dielectrophoresis AND in part, it pulls chromosomes away from daughter cells." One patient with breast cancer has had complete tumor shrinkage AND the others in that study have had tumor reductions of 83%-96%. TTF has been used as monotherapy without systemic effects AND appears to act synergistically with chemotherapy, Dr. Palti said. Approximately 140 patients with recurrent glioblastoma are enrolled in the trial presented this past weekend by Dr. Palti. Half are being treated with TTF AND half are receiving the best conventional treatment for recurrent glioblastoma. Time to disease recurrence has doubled from 10 weeks to 20 weeks AND survival has increased from 6 months to a median of 12 months. "Many patients are surviving as long as 2 years AND some patients are still alive at 4 years," Dr. Palti reported. "We can't really say what the survival is yet, because (many of these) patients are still alive." "Many of these patients are able to work AND to take care of themselves," he added. "The FDA needs 236 patients with a median of 6 months of follow-up data for device approval," he said, but the results to date appear promising. http://www.novocuretrial.com/about.html

http://www.novocuretrial.com/print_version.pdf

אין שום דבר חדש בפיתוח הישראלי הטכנולוגיה הזו עובדת מי שנת 1930 רק מנסים לתת לזה רקע מדעי ומחקרי בלבד וזה דבר מאוד חשוב הטכנולוגייה הזו עובדת בקלינקות בגרמניה וגם בישראל וגם בבתי החולים בעולם ובישראל אין דבר חדש בזה כול מכשירי MRI מבוסס על מגנט רב עוצמה העובדים בבתי החולים הם בעלי יכולת ריפוי וחלמה של כול הגידולים הסרטניים במוח וקטילה וחיסול של גידולים סרטניים בגוף זה חלק קטן מאוד מהיכולת של ממכשירי MRI שרבים מהרופאים הבכירים מודעים לזה פשוט לא מעונינים להישתמש אם זה לריפוי והחלמה מכוון שזה יעצור את תזרים המזומנים לבתי החולים זה לא כלכלי חג פסח כשר ושמח